Cephalexin Anhydrous

Cephalexin Anhydrous

SCHEMBL40988

CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1.Cl

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

dacAdacBdacCftsImrcAmrcBmrdA

The experimentally established mechanism targets of Cephalexin Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 7/20 0.98
MAPT P10636 7/20 0.98
ALDH1A1 P00352 6/20 0.98
KMT2A Q03164 5/20 0.98
CYP3A4 P08684 4/20 0.98
SLC15A2 Q16348 3/20 0.98
HPGD P15428 3/20 0.98
TDP1 Q9NUW8 3/20 0.98
BLM P54132 2/20 0.98
CYP2C19 P33261 2/20 0.98
MAPK1 P28482 2/20 0.98
ADRA1A P35348 1/20 0.98
HTR2B P41595 1/20 0.98
MEN1 O00255 4/20 0.83
LMNA P02545 2/20 0.83
ESR1 P03372 1/20 0.83
SLC22A6 Q4U2R8 1/20 0.83
SLC22A8 Q8TCC7 1/20 0.83
KDM4E B2RXH2 6/20 0.76
CYP2C9 P11712 2/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cephalexin Anhydrous SCHEMBL5489216 1.00 HSD17B10 (0.98) HSD17B10MAPTALDH1A1KMT2ACYP3A4
Cephalexin Anhydrous SCHEMBL5049268 1.00 HSD17B10 (0.98) HSD17B10MAPTALDH1A1KMT2ACYP3A4
Cephalexin Anhydrous SCHEMBL27562810 1.00 HSD17B10 (0.98) HSD17B10MAPTALDH1A1KMT2ACYP3A4
Cephalexin Anhydrous SCHEMBL5049273 1.00 HSD17B10 (0.98) HSD17B10MAPTALDH1A1KMT2ACYP3A4
Cephalexin Anhydrous SCHEMBL582342 0.99 HSD17B10 (0.98) HSD17B10MAPTALDH1A1KMT2ACYP3A4
Cephalexin Anhydrous SCHEMBL27742537 0.99 HSD17B10 (0.98) HSD17B10MAPTALDH1A1KMT2ACYP3A4
Cephalexin Anhydrous SCHEMBL10529259 0.99 HSD17B10 (0.96) HSD17B10MAPTALDH1A1KMT2ACYP3A4
Cephalexin Anhydrous SCHEMBL4928314 0.99 HSD17B10 (0.98) HSD17B10MAPTALDH1A1KMT2ACYP3A4
Cephalexin Anhydrous SCHEMBL4928321 0.99 HSD17B10 (0.98) HSD17B10MAPTALDH1A1KMT2ACYP3A4
Cephalexin Anhydrous SCHEMBL2961 0.99 HSD17B10 (1.00) HSD17B10MAPTALDH1A1KMT2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2359 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12274830-B2 Nitric oxide inhalation therapy for infants with bronchiolitis BEYOND AIR LTD (IL) 2025-04-15 US claimed
US-20240173512-A1 METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS STREETERVILLE CAPITAL, LLC 2024-05-30 US claimed
US-11890421-B2 Methods for potentiating antimicrobial agents BEYOND AIR LTD (IL) 2024-02-06 US claimed
CN-117384259-A Cell penetrating peptides based on influenza virus M2 proteins 中国医学科学院基础医学研究所 2024-01-12 CN claimed
CN-114053206-A Medicinal floating preparation and preparation method thereof 常州恒邦药业有限公司 2022-02-18 CN claimed
CN-114053207-A Sustained-release pharmaceutical composition and preparation method thereof 常州恒邦药业有限公司 2022-02-18 CN claimed
US-20220008334-A1 GASTRIC RETENTIVE DEVICES CLEXIO BIOSCIENCES LTD. (IL) 2022-01-13 US claimed
US-11147766-B2 Gastric retentive devices CLEXIO BIOSCIENCES LTD. (IL) 2021-10-19 US claimed
CN-112912386-A Cell penetrating peptide based on influenza virus M2 protein 中国医学科学院基础医学研究所 2021-06-04 CN claimed
US-20200246573-A1 NITRIC OXIDE INHALATION THERAPY FOR INFANTS WITH BRONCHIOLITIS STREETERVILLE CAPITAL, LLC 2020-08-06 US claimed
US-20020188196-A1 Cavity-filling biopsy site markers SENORX, INC. 2002-12-12 US claimed
US-6245735-B1 CONJUGATE OF ANTIBIOTIC AND POLYPEPTIDE OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR OR LIPOPOLYSACCHARIDE BINDING FRAGMENT THE BRIGHAM AND WOMEN'S HOSPITAL, INC. 2001-06-12 US claimed
EP-0976755-A1 Improvements in or relating to beta lactam production BIOCHEMIE Gesellschaft m.b.H. (AT) 2000-02-02 EP claimed
EP-0528941-A4 PROCESS FOR PREPARING CEPHALEXIN MONOHYDRATE BIOCRAFT LABORATORIES INC (US) 1994-07-06 EP claimed
EP-0528941-A1 PROCESS FOR PREPARING CEPHALEXIN MONOHYDRATE BIOCRAFT LABORATORIES, Inc. (US) 1993-03-03 EP claimed
US-5142043-A PROCESS FOR PREPARING CEPHALEXIN MONOHYDRATE BIOCRAFT LABORATORIES, INC. (US) 1992-08-25 US claimed
WO-1991017166-A1 PROCESS FOR PREPARING CEPHALEXIN MONOHYDRATE BIOCRAFT LABORATORIES, INC. (US) 1991-11-14 WO claimed
EP-0143658-B1 IMPROVEMENTS IN OR RELATING TO CEPHALOSPORIN DERIVATIVES ELI LILLY AND COMPANY (US) 1989-03-22 EP claimed
US-4775751-A Process for cephalexin hydrochloride alcoholates ELI LILLY & COMPANY (US) 1988-10-04 US claimed
US-4615698-A Total agent osmotic delivery system ALZA CORPORATION (US) 1986-10-07 US claimed